×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
WSAV-TV
BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates bexotegrast development in IPF.
6 hours ago
Pliant Therapeutics to Participate in Upcoming Investor Events
WATE 6 On Your Side
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology...
5 days ago
Pliant Therapeutics (NASDAQ:PLRX) investors are sitting on a loss of 69% if they invested a year ago
Yahoo Movies Canada
Even the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of Pliant Therapeutics, Inc. (NASDAQ:PLRX) have...
2 days ago
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Yahoo Finance
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Positive DSMB safety review...
5 months ago
Pliant Therapeutics Inc CFO Keith Cummings Sells 9,781 Shares
Yahoo Finance
The transaction was executed at an average price of $17.23 per share, resulting in a total value of $168,553.63.Pliant Therapeutics Inc is a...
3 months ago
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary ...
GlobeNewswire
Acceptance by European Union and other global health authorities of the pivotal, adaptivePhase 2b/3 trial will significantly shorten...
1 month ago
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
GlobeNewswire
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in...
2 months ago
Pliant Therapeutics recruits patients for bexotegrast trial amidst lPF race
Pharmaceutical Technology
Pliant Therapeutics doubles down on enrolment for a Phase IIb IPF trial as other industry players also investigate new IPF therapies.
4 months ago
Pliant Therapeutics (FRA:9PT) 5-Day RSI : 37.44 (As of May. 02, 2024)
GuruFocus
What is Pliant Therapeutics 5-Day RSI? The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements.
4 days ago
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial ...
GlobeNewswire
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events;...
3 months ago